A monthly 300 mg dose of ianalumab demonstrated greater reductions in disease activity vs. placebo at 48 weeks among patients with Sjögren’s disease, according to data from two trials published in the New England Journal of Medicine.
“Currently, there are no approved targeted therapies available for the treatment of Sjögren’s disease,” Xavier Mariette, MD, PhD, of Paris-Saclay University and Bicêtre Hospital, in Le Kremlin-Bicêtre, France, and colleagues wrote. “Despite having a clear mechanistic rationale, the testing of multiple biologic and targeted approaches

The FDA accepted uniQure's AMT-130 application for Huntington's disease, granted priority review, and set a May 1, 2027, target decision date while approval remains uncertain.

A preliminary study of more than 44 million U.S. births linked pre-pregnancy diabetes and chronic hypertension to higher risks of critical congenital heart disease, while emphasizing the limits of observational data.

A federal judge sentenced Glendale doctor Violetta Mailyan to 15 years for billing Medicare more than $45 million for unnecessary or nonexistent Botox treatments and falsifying patient records.

Redeemer Health has filed for Chapter 11 bankruptcy, keeping Holy Redeemer Hospital and other services open while the Catholic nonprofit considers a sale, restructuring or possible closure.

A preliminary analysis found higher odds of self-reported stroke among occasional cannabis users, but researchers cautioned that the observational, unreviewed study cannot establish cause and effect.

The FDA has tentatively approved Dr. Reddy's generic injectable lenacapavir for HIV prevention, potentially bringing a twice-yearly shot costing about $40 annually to 120 countries.

The midterm elections may determine congressional control and influence future health policy, but Medicaid work requirements, enrollment deadlines and other changes will proceed on existing timelines.

A study of more than 2.5 million U.S. heart attack deaths found rural residents were nearly three times as likely to die before reaching a hospital, underscoring emergency-care access gaps.

A preliminary study of 52,330 Israeli women found similar rates of heart attack, stroke, blood clots and early death among hormone therapy users and nonusers, though it cannot prove safety.